

SUPPLEMENTARY TABLES

Table S1: Clinical-pathologic characteristics of IBD and psoriatic patients with PP treated with Adalimumab.

Characteristics ^a	IBD patients with PP (n=11)	Psoriatic patients with PP (n=23)	<i>p value</i> *
Sex			
Male	3 (27.3%)	9 (39.1%)	
Female	8 (72.7%)	14 (60.9%)	0.06
Number of psoriatic lesion locations			
1	1 (9.1%)	14 (73.7%)	
2	3 (27.3%)	2 (10.5%)	
3 or more	7 (63.6%)	3 (15.8%)	0.003
Psoriatic lesions locations			
Lower limbs	3 (9.7%)	5 (18.5%)	
Upper limbs	1 (3.2%)	3 (11.1%)	
Armpits	4 (12.9%)	0 (0.0%)	
Nipple	1 (3.2%)	0 (0.0%)	
Scalp	8 (25.8%)	1 (3.7%)	
Genitals	4 (12.9%)	2 (7.4%)	
Hands	0 (0.0%)	4 (14.8%)	
Umbilicus	3 (9.7%)	0 (0.0%)	
Retroauricular	4 (12.9%)	3 (11.1%)	
Back	1 (3.2%)	2 (7.4%)	
Trunk	1 (3.2%)	2 (7.4%)	
Nails	0 (0.0%)	1 (3.7%)	
Face	1 (3.2%)	2 (7.4%)	
Suberitrodermic (diffuse cutaneous involvement)	0 (0.0%)	2 (7.4%)	0.04
Pruritus			
No	6 (50.0%)	4 (18.2%)	
Yes	6 (50.0%)	18 (81.8%)	0.05
Number of months from the beginning of therapy to the development of the paradoxical effect (Mean ± standard error)	9 (± 1.9)	40.8 (±8.3)	0.009

*In bold statistically significant results

^aSome data for each pathologic characteristic are not available

Abbreviations: IBD: Inflammatory bowel diseases; PP: Paradoxical psoriasis.

Table S2: Distribution of psoriatic patients with and without PP according to genotype frequencies of the six SNPs analyzed.

Gene	SNP	Genotype	Psoriatic patients with PP (n=23)	Psoriatic patients without PP (n=70)	p value*
			n (%)	n (%)	
HLA-Cw06	rs10484554	C/C	9 (39.1%)	27 (38.6%)	0.7
		C/T	9 (39.1%)	33 (47.1%)	
		T/T	5 (21.7%)	10 (14.3%)	
		Per-allele	OR 1.1 (95%CI 0.6-2.2) p=0.7		
IL23R	rs11209026	G/G	22 (95.6%)	60 (85.7%)	0.2
		G/A	1 (4.4%)	10 (14.3%)	
		A/A	0 (0.0%)	0 (0.0%)	
		Per-allele	OR 0.3 (95%CI 0.03-2.3) p=0.2		
IL23R	rs10789229	T/T	11 (47.8%)	29 (41.4%)	0.7
		T/C	8 (34.8%)	31 (44.3%)	
		C/C	4 (17.4%)	10 (14.3%)	
		Per-allele	OR 0.9 (95%CI 0.5-1.8) P=0.8		
TNFA	rs1799964	T/T	13 (56.5%)	42 (60.0%)	0.2
		T/C	7 (30.4%)	26 (37.1%)	
		C/C	3 (13.0%)	2 (2.9%)	
		Per-allele	OR 1.4 (95% CI 0.7-3.1) p=0.3		
TNFA	rs1800629	G/G	21 (91.3%)	64 (91.4%)	0.6
		G/A	1 (4.4%)	5 (7.1%)	
		A/A	1 (4.3%)	1 (1.4%)	
		Per-allele	OR 1.2 (95% CI 0.4-4) p=0.7		
IFIH1	rs1990760	T/T	8 (34.8%)	24 (34.3%)	0.7
		T/C	11 (47.8%)	28 (40.0%)	
		C/C	4 (17.4%)	18 (25.7%)	
		Per-allele	OR 0.8 (95% CI 0.5-1.6) p=0.6		

*In bold statistically significant results

Abbreviations: PP: Paradoxical psoriasis; IFIH1: Interferon induced with helicase C domain 1; TNF- α : Tumor necrosis factor-alpha.

Table S3: Distribution of IBD patients with PP and psoriatic patients without PP treated with Adalimumab according to genotype frequencies of the six SNPs analyzed.

Gene	SNP	Genotype	IBD patients with PP (n=11)	Psoriatic patients without PP (n=70)	p value*
			N (%)	N (%)	
<i>HLA-Cw06</i>	rs10484554	C/C	9 (81.8%)	27 (38.6%)	0.02
		C/T	2 (18.2%)	33 (47.1%)	
		T/T	0 (0.0%)	10 (14.3%)	
		Per-allele	OR 0.2 (95% CI 0.04-0.7) p=0.02		
<i>IL23R</i>	rs11209026	G/G	9 (81.8%)	60 (85.7%)	0.73
		G/A	2 (18.2%)	10 (14.3%)	
		A/A	0 (0.0%)	0 (0.0%)	
		Per-allele	OR 1.33 (95% CI 0.3-7.1) p=0.7		
<i>IL23R</i>	rs10789229	T/T	8 (72.7%)	29 (41.4%)	0.02
		T/C	0 (0.0%)	31 (44.3%)	
		C/C	3 (27.3%)	10 (14.3%)	
		Per-allele	OR 0.7 (95% CI 0.3-1.8) p=0.4		
<i>TNFA</i>	rs1799964	T/T	4 (36.4%)	42 (60.0%)	0.06
		T/C	5 (45.5%)	26 (37.1%)	
		C/C	2 (18.1%)	2 (2.9%)	
		Per-allele	OR 2.8 (95% CI 1-7.7) p=0.05		
<i>TNFA</i>	rs1800629	G/G	11 (100%)	64 (91.4%)	0.6
		G/A	0 (0.0%)	5 (7.1%)	
		A/A	0 (0.0%)	1 (1.4%)	
		Per-allele	-		
<i>IFIH1</i>	rs1990760	T/T	4 (36.3%)	24 (34.3%)	0.8
		T/C	5 (45.5%)	28 (40.0%)	
		C/C	2 (18.2%)	18 (25.7%)	
		Per-allele	OR 0.8 (95% CI 0.4-2) p= 0.7		

*In bold statistically significant results

Abbreviations: IBD: Inflammatory bowel diseases; PP: Paradoxical psoriasis; IFIH1: Interferon induced with helicase C domain 1; TNF- α : Tumor necrosis factor-alpha.